E-DRUG: DNDi receives £6.5m from UK to support neglected diseases R&D
---------------------------------------------------------------------
For Immediate Release
UK government commits £6.5 million to DNDi's research for new medicines for neglected diseases
Geneva, March 9, 2005: The UK's Department of International Development (DFID) today granted £6.5 million (9.5 million Euros) to the Drugs for Neglected Diseases initiative (DNDi) for essential research and development of drugs for neglected diseases such as human African trypanosomiasis, leishmaniasis, Chagas disease, and malaria.
"We congratulate the UK government for this generous commitment to R&D that will make available safe, effective, practical-to-use, and affordable drugs so desperately needed by patients," remarked Dr. Bernard Pecoul, Executive Director of DNDi. "This grant gives hope to millions of patients who unacceptably die or suffer from these diseases in the poorest regions of the world."
The grant, spread over three years, is critical support for DNDi to further develop its North and South public and private partnerships to address the significant drug development gap for neglected tropical diseases. With a current portfolio of 20 projects, DNDi aims to develop 6 to 8 new, improved, and field-relevant drugs by 2014, including two new malaria treatments that will be registered by the end of 2006.
Gareth Thomas, UK International Development Minister, said: "Forgotten and neglected diseases threaten up to half a billion people worldwide. Developing better and new treatments, and giving people the tools to tackle disease, is vital if we are to address the long-term health, not only of individuals, but of poor nations too. Funding initiatives such as these are key to our fight against poverty."
A massive governmental commitment is needed to address the urgent needs of patients suffering from these poverty-related diseases. While the establishment of product development partnerships (PDPs) like DNDi represents an important evolution for neglected diseases research, these PDPs have mainly been supported by philanthropic organizations until now. For instance, Médecins Sans Frontières (MSF), catalyzed the creation of DNDi with a 2003 commitment of 25 million Euros. To sustain the momentum slowly achieved in this field of research, however, public sector investment similar to DFID's is urgently required to tackle public health needs.
Dr. Pecoul said, "By honoring the G8 pledge to support drug research and development for neglected diseases, the UK government via its funding of DNDi and other PDPs is leading the way in accelerating the fight against neglected diseases. We urge other governments to join the fight against these devastating diseases."
The Drugs for Neglected Diseases Initiative (DNDi) is an independent, not-for-profit drug development initiative established in 2003 by Médecins sans Frontières (MSF) along with five public sector institutions - the Oswaldo Cruz Foundation from Brazil, the Indian Council of Medical Research, the Kenya Medical Research Institute, the Ministry of Health of Malaysiam, and France's Pasteur Institute - and the UNICEF/UNDP/World Bank/WHO's Special Programme for Research and Training in Tropical Diseases (TDR) acting as a permanent observer to the initiative. With a current portfolio of 20 projects, DNDi aims to develop new, improved, and field-relevant drugs for neglected diseases - such as leishmaniasis, human African trypanosomiasis, and Chagas disease - that afflict the very poor in developing countries. DNDi also raises awareness about the need for greater R&D for neglected diseases and strengthens existing research capacity in disease-endemic countries.
For further information, please consult http://www.dndi.org
For more information, or to arrange an interview with Dr Bernard Pecoul, contact Ann-Marie SEVCSIK at amsevcsik@dndi.org; +1-646-258-8131 or +41 (0)79 814 9147)